Cancer Genetics to Present at Marcum MicroCap Conference
By Jamie on May 23 2013
RUTHERFORD, NJ, May 23, 2013 — Cancer Genetics, Inc. (OTCQB: CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics, will present at the second annual Marcum MicroCap Conference on Thursday, May 30, 2013 at 2:30 p.m. ET at the Grand Hyatt New York in New York City. The Marcum MicroCap Conference is […]
Continue ReadingMayo Clinic Forms Joint Venture with Cancer Genetics
By Italia on May 22 2013
OncoSpire Genomics will seek to discover and commercialize biomarkers for multiple cancer types RUTHERFORD, NJ, May 22, 2013 — Mayo Clinic (“Mayo”) and Cancer Genetics Inc. (OTCQB: CGIX) today launched OncoSpire Genomics (“OncoSpire”), a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing. “Individualized […]
Continue ReadingCancer Genetics Signs Agreement with MultiPlan
By Jamie on May 21 2013
RUTHERFORD, NJ, May 21, 2013 — Cancer Genetics, Inc. (OTCQB: CGIX) (“CGI” or the “Company”), a leader in oncology-focused personalized medicine, has entered into an agreement with MultiPlan, Inc. (“MultiPlan”), the industry’s most comprehensive provider of healthcare cost management solutions. As a participating provider in the PHCS and MultiPlan networks, CGI will be able to […]
Continue ReadingCancer Genetics to Attend ASCO Annual Meeting
By Italia on May 20 2013
RUTHERFORD, NJ, May 20, 2013 — Cancer Genetics, Inc. (OTCQB: CGIX) (“CGI” or the “Company”), a leader in oncology-focused personalized medicine, will attend for the first time the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting on May 31-June 4, 2013 at McCormick Place in Chicago. CGI will be at stand number 19120 during […]
Continue ReadingCancer Genetics Announces First Quarter 2013 Financial Results and Significant Business and Portfolio Progress
By Italia on May 15 2013
First quarter revenue increased 46% YoY Clinical test volume increased 19% YoY Institutional client base grows to 42% of revenues DNA-Probe product manufacturing moved to India, reducing cost of goods RUTHERFORD, N.J.–Cancer Genetics, Inc. (OTCQB: CGIX) (“CGI” or the “Company”) is an emerging leader in the diagnosis and disease management for the most complex […]
Continue ReadingCancer Genetics to Sponsor and Host Roundtable at BioNJ Diagnostics & Personalized Medicine Innovation Summit
By Italia on May 14 2013
RUTHERFORD, NJ, May 14, 2013, /Business Wire/ — Cancer Genetics, Inc. (OTCQB: CGIX) (“CGI” or the “Company”), a leader in oncology-focused personalized medicine, will sponsor and host a roundtable discussion at the second annual BioNJ Diagnostics & Personalized Medicine Innovation Summit on Thursday, June 6, 2013 at Sanofi’s U.S. headquarters in Bridgewater, NJ. The BioNJ […]
Continue ReadingCancer Genetics Announces Distribution Partnership with Nikon Instruments
By Italia on May 8 2013
Cancer Genetics, Inc.’s (OTCQB: CGIX) (“CGI” or the “Company”) wholly-owned subsidiary, Cancer Genetics Italia, S.r.l. (“CGI Italia”), has entered into an agreement with Nikon Instruments S.p.A. (“Nikon”) for the distribution of oncology-focused DNA Probes intended for fluorescence in situ hybridization (“FISH”) in the Italian market. This new partnership extends CGI’s global distribution network and provides […]
Continue ReadingCancer Genetics Announces Distribution Partnership with Nikon Instruments
By Italia on May 8 2013
Cancer Genetics, Inc.’s (OTCQB: CGIX) (“CGI” or the “Company”) wholly-owned subsidiary, Cancer Genetics Italia, S.r.l. (“CGI Italia”), has entered into an agreement with Nikon Instruments S.p.A. (“Nikon”) for the distribution of oncology-focused DNA Probes intended for fluorescence in situ hybridization (“FISH”) in the Italian market. This new partnership extends CGI’s global distribution network and provides […]
Continue Reading